Academic Journals Database
Disseminating quality controlled scientific knowledge

Treatment of Recurrent Platinum-Sensitive Epithelial Ovarian Cancer

Author(s): Joyce F Liu | Ursula A Matulonis

Journal: European Journal of Clinical & Medical Oncology
ISSN 1759-8958

Volume: 2;
Issue: 2;
Start page: 75;
Date: 2010;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: ovarian cancer | recurrent disease | cytotoxic chemotherapy | secondary cytoreductive surgery | platinum sensitive

Ovarian cancer remains a leading cause of cancer death among women, with an estimated 125000 deaths worldwide. Newly diagnosed ovarian cancer is very responsive to first-line platinum-based therapy, but the majority of patients will have disease recurrence. Patients in whom disease recurs more than 6 months after completing prior platinum-based treatment are considered to have platinum-sensitive disease, and questions remain regarding the optimal management of their disease. Many options exist for these patients, including systemic chemotherapy, and in specific circumstances, secondary cytoreductive surgery or radioablative techniques can be considered for patients with localized recurrences and long disease-free intervals. For patients receiving systemic chemotherapy, data from clinical trials suggest that combination platinum-based chemotherapy should be considered in this setting for patients in whom the toxicities would be acceptable, although the optimal regimen remains unclear. Ongoing investigations seek to address the role of secondary cytoreductive surgery, the optimal therapy for recurrent platinum-sensitive disease, the therapeutic potential of non-platinum-based therapies, and the role of biological therapy in this setting.
RPA Switzerland

Robotic Process Automation Switzerland


Tango Jona
Tangokurs Rapperswil-Jona